Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $143.65 | Total: $718.25 |
| 1 | 10 | $121.68 | Total: $1,216.80 |
| 1 | 25 | $103.09 | Total: $2,577.25 |
| 1 | 50 | $87.88 | Total: $4,394.00 |
| 1 | 100 | $76.05 | Total: $7,605.00 |
Overview
Gly-?-MCA is an orally bioactive, enteroselective and potent inhibitor of the farnesoid X receptor (FXR), a bile acid, used in the study of obesity and diabetes.
Chemical Properties
| Molecular Formula | C26H43NO6 |
| Molecular Weight | 465.62 |
| CAS Numbers | 66225-78-3 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | C[C@H](CCC(=O)NCC(O)=O)C1CCC2C3[C@@H](O)[C@@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)C3CC[C@]12C |
Storage and Handling
0C Short Term, -20C Long Term
References
Jiang C, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun. 2015 Dec 15;6 10166.